Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Coming Soon – October 2019
Approximately 80% of rare diseases have a genetic etiology. Gene therapies hold the potential to transform the treatment of rare diseases and may provide a functional cure for some. However, these innovative new treatment options must come with equally innovative programs to optimize access in a global healthcare market that is still grappling with how to fairly assess their value and absorb their higher upfront costs. Nonetheless, the pipeline for gene therapies is burgeoning, with large pharmaceutical companies (e.g., Novartis, Johnson & Johnson) taking an increasing stake in this arena. Here we will explore the clinical and commercial potential of gene therapies in key therapeutic areas (e.g., neurology, ophthalmology, hematology).
United States, EU5, Japan
Approximately 20 country-specific interviews with thought-leading gene therapy experts
Supported by survey data collected for this and other DRG research
Diagnosed prevalent and/or incident patient populations eligible for gene therapies in covered indications
10-year, annualized, drug-level sales and patient share of key gene therapies through 2028
Pipeline gene therapy coverage for select indications across therapy areas including hematology, ophthalmology, and neurology
Disease Landscape & Forecast provides comprehensive market intelligence
with world-class epidemiology, keen insight into current treatment paradigms, indepth
pipeline assessments, and drug forecasts supported by detailed primary
and secondary research.
Already a Client? Log in to access this report.
Claudia is a Senior Business Insights analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing on niche and rare indications. Before joining DRG, she held a management and strategy consultant position at Precision Medicine Group, where she worked for clients in the biopharmaceutical, medical device and diagnostic industries. Claudia completed her Master’s in Management at Harvard University; she also holds a in medical genetics from Brescia University in Italy and a BS/MS degree in medical biotechnology from University of Milano in Italy.